Newsroom
Sorted by: Latest
-
Kyowa Kirin und Knight Therapeutics schließen eine exklusive Vertriebsvereinbarung für POTELIGEO® (Mogamulizumab) für Patienten mit kutanem T-Zell-Lymphom (CTCL) in ganz Lateinamerika
GALASHIELS & MARLOW, GB--(BUSINESS WIRE)--Kyowa Kirin International, eine hundertprozentige Tochtergesellschaft der Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), gab heute die Unterzeichnung einer exklusiven Vertriebsvereinbarung mit Knight Therapeutics („Knight“) (TSX: GUD) über den Vertrieb von Mogamulizumab in ausgewählten Ländern Lateinamerikas bekannt. Gemäß den Vertragsbedingungen ist Knight dafür verantwortlich, die erforderlichen behördlichen Genehmigungen einzuholen und Mogamulizumab...
-
Forbright, Inc. Schedules Release of Third Quarter 2026 Financial Results
CHEVY CHASE, Md.--(BUSINESS WIRE)--Forbright, Inc. (Nasdaq: FRBT) (the "Company"), the parent company of wholly-owned subsidiary Forbright Bank, has scheduled the release of its third quarter 2026 financial results for Thursday, October 29, 2026, at approximately 6:00 a.m. ET. The earnings press release and investor presentation will be available on the Company’s Investor Relations website at ir.forbrightbank.com. Forbright, Inc. will host a conference call at 8:00 a.m. ET on October 29, 2026,...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Powerful Medical and corpuls Partner to Bring Queen of Hearts AI-Powered Heart Attack Detection to Prehospital Care
BRATISLAVA, Slovakia--(BUSINESS WIRE)--Powerful Medical, developer of the PMcardio AI cardiology platform, and corpuls, Europe's leading manufacturer of monitor/defibrillator systems for prehospital emergency medical services, today announced a strategic partnership to integrate Powerful Medical's Queen of Hearts AI ECG model directly into the corpuls platform used by emergency care professionals in over 70 countries globally. Health care professionals recording a 12-lead ECG on a corpuls3 devi...
-
LEO Pharma presents new data on delgocitinib cream at EADV 2026 highlighting real-world outcomes in adults and new adolescent data in Chronic Hand Eczema (CHE)
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, has presented new data on delgocitinib cream in Chronic Hand Eczema (CHE) at the 35th European Academy of Dermatology and Venereology (EADV) Congress, held from 30 September to 3 October 2026 in Vienna, Austria. In total, six delgocitinib presentations feature in the company’s programme at the congress, including one oral presentation and five ePosters, spanning adults and adolescents, controlled clinica...
-
Roquette apresentará soluções farmacêuticas de ponta a ponta para formulações centradas no paciente na CPHI Milão 2026
LILLE, França--(BUSINESS WIRE)--A Roquette apresentará seu portfólio completo de excipientes farmacêuticos, soluções de administração de fármacos e expertise técnica de ponta na CPHI Milão 2026 na Itália, onde a empresa receberá visitantes no estande 1A18 no salão de excipientes. No evento global deste ano, a Roquette destacará as principais marcas de produtos que apoiam o desempenho das formulações, a administração de fármacos centrada no paciente e a inovação biofarmacêutica, incluindo os éte...
-
Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced two new clinical experts will join its global medical leadership team, led by Global Chief Medical Officer Pat Carroll, MD. Kultar Garcha, MD, will serve as Chief Medical Officer of the UK and EMEA, and Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, will serve as Chief Medical Officer of Hims Australia. The appointments mark the company’s latest step in streng...
-
Defense Health Agency Selects Hypori to Secure Clinical Dictation on Clinicians' Personal Phones
RESTON, Va.--(BUSINESS WIRE)--Hypori, the leading secure mobile access and virtual mobile infrastructure (VMI) platform, today announced that the Defense Health Agency (DHA) deployed Hypori's VMI platform to give clinicians secure, hands-free access to Oracle Health's ambient clinical dictation technology (Clinical Agent AI) from their own personal phones. The integration ensures personal health information (PHI), controlled unclassified information (CUI), and Department of War (DoW) data are n...
-
Monroe Capital Prices $398.9 Million Private Credit CLO
CHICAGO--(BUSINESS WIRE)--Monroe Capital LLC (“Monroe”), a leading private credit asset manager, today announced the successful pricing of Monroe Capital PC CLO II, LP, a $398.9 million collateralized loan obligation (“CLO”) transaction. The transaction represents Monroe’s second new-issue CLO completed in 2026 and its fourth CLO transaction over the past 12 months. The CLO is collateralized primarily by a diversified portfolio of senior secured loans to lower middle-market and traditional midd...